Coya Therapeutics, Inc. ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with ...

Mr. Quigley most recently led McKinsey & Company’s Private Capital practice and previously led various Life Sciences practices at the ...

Among 27 men who received 25 mL to 1.5 L of a water-like liquid known as perfluorodecalin, 20 were able to retain it within ...

Pennsylvania-based Conestoga Capital Advisors sold 855,435 Vertex shares for an estimated $24.8 million based on average ...

Jupiter Endovascular, which was formed by Neptune Medical a little more than a year ago, shared positive results from the ...

Biopharma has finally begun catching up with the overall stock market, as shares of the top three biopharma exchange traded funds (ETFs) jumped well into double digits over the past six months.

BioMarin will host a conference call and webcast to discuss third quarter 2025 financial results today, Monday, October 27, 2025, at 4:30 p.m. ET. This event can be accessed through this link or on ...

After pioneering haptic gloves for virtual reality, Tokyo-based startup Diver-X is taking aim at one of the most familiar computer tools: the ...